Status:
COMPLETED
Comparison of Sleep Disordered Breathing Events Detected by the CPAP Device "prismaLine" With Polysomnography
Lead Sponsor:
Institut für Pneumologie Hagen Ambrock eV
Collaborating Sponsors:
Heinen und Löwenstein GmbH & Co. KG
Conditions:
Sleep Apnea Syndromes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Evaluation of residual sleep disordered breathing (SDB) under continuous positive airway pressure (CPAP) therapy with comparison of the automatic detected SDB event indices from CPAP machines with man...
Detailed Description
The evaluation of residual sleep disordered breathing (SDB) in sleep apnea (SA) after initiation of continuous positive airway pressure (CPAP) therapy is important to verify the therapeutic success. I...
Eligibility Criteria
Inclusion
- PSG diagnostic not older than 3 month,
- AHI\>15, CPAP indication,
- age \>18,
- nasal CPAP mask,
- written informed consent
Exclusion
- CPAP contraindication,
- participation in another clinical trial
Key Trial Info
Start Date :
January 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04407949
Start Date
January 17 2019
End Date
September 30 2020
Last Update
October 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kliniken Essen-Mitte, Evang. Huyssens-Stiftung/Knappschaft gGmbH
Essen, North Rhine-Westphalia, Germany, 45276